Dinevska M, Widodo S, Furst L, Cuzcano L, Fang Y, Mangiola S
Cell Oncol (Dordr). 2022; 46(3):589-602.
PMID: 36567397
DOI: 10.1007/s13402-022-00763-9.
Shojaee P, Mornata F, Deutsch A, Locati M, Hatzikirou H
Front Immunol. 2022; 13:1050067.
PMID: 36439180
PMC: 9685623.
DOI: 10.3389/fimmu.2022.1050067.
Beach C, MacLean D, Majorova D, Arnold J, Olcina M
Front Oncol. 2022; 12:1020606.
PMID: 36249052
PMC: 9559862.
DOI: 10.3389/fonc.2022.1020606.
Izci M, Maksoudian C, Manshian B, Soenen S
Chem Rev. 2021; 121(3):1746-1803.
PMID: 33445874
PMC: 7883342.
DOI: 10.1021/acs.chemrev.0c00779.
Zhang J, Spath S, Weissman S, Katz S
Methods Mol Biol. 2019; 2097:139-171.
PMID: 31776925
PMC: 7062409.
DOI: 10.1007/978-1-0716-0203-4_10.
Hypoxic Macrophage-Derived VEGF Promotes Proliferation and Invasion of Gastric Cancer Cells.
Ma F, Zhang B, Ji S, Hu H, Kong Y, Hua Y
Dig Dis Sci. 2019; 64(11):3154-3163.
PMID: 31102128
DOI: 10.1007/s10620-019-05656-w.
Harnessing Biology to Deliver Therapeutic and Imaging Entities via Cell-Based Methods.
Joshi B, Hardie J, Farkas M
Chemistry. 2018; 24(35):8717-8726.
PMID: 29543990
PMC: 6174085.
DOI: 10.1002/chem.201706180.
Hypoxia-inducible factor 1α is Essential for Macrophage-mediated Erythroblast Proliferation in Acute Friend Retrovirus Infection.
Schreiber T, Quinting T, Dittmer U, Fandrey J, Sutter K
Sci Rep. 2017; 7(1):17236.
PMID: 29222473
PMC: 5722883.
DOI: 10.1038/s41598-017-17324-y.
Nanomedicine engulfed by macrophages for targeted tumor therapy.
Li S, Feng S, Ding L, Liu Y, Zhu Q, Qian Z
Int J Nanomedicine. 2016; 11:4107-24.
PMID: 27601898
PMC: 5003564.
DOI: 10.2147/IJN.S110146.
Immune Cells in Cancer Therapy and Drug Delivery.
Eyileten C, Majchrzak K, Pilch Z, Tonecka K, Mucha J, Taciak B
Mediators Inflamm. 2016; 2016:5230219.
PMID: 27212807
PMC: 4860248.
DOI: 10.1155/2016/5230219.
Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.
Patel A, Sant S
Biotechnol Adv. 2016; 34(5):803-812.
PMID: 27143654
PMC: 4947437.
DOI: 10.1016/j.biotechadv.2016.04.005.
Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment.
Ivey J, Bonakdar M, Kanitkar A, Davalos R, Verbridge S
Cancer Lett. 2016; 380(1):330-9.
PMID: 26724680
PMC: 4919249.
DOI: 10.1016/j.canlet.2015.12.019.
Targeted nanosystems: Advances in targeted dendrimers for cancer therapy.
Yang H
Nanomedicine. 2015; 12(2):309-16.
PMID: 26706410
PMC: 4789125.
DOI: 10.1016/j.nano.2015.11.012.
Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia.
Song M, Liu T, Shi C, Zhang X, Chen X
ACS Nano. 2015; 10(1):633-647.
PMID: 26650065
PMC: 5242343.
DOI: 10.1021/acsnano.5b06779.
Engineering macrophages to control the inflammatory response and angiogenesis.
Eaton K, Yang H, Giachelli C, Scatena M
Exp Cell Res. 2015; 339(2):300-9.
PMID: 26610863
PMC: 4679554.
DOI: 10.1016/j.yexcr.2015.11.021.
Irradiation Enhances the Ability of Monocytes as Nanoparticle Carrier for Cancer Therapy.
Jiang P, Yu C, Yen C, Woo C, Lo S, Huang Y
PLoS One. 2015; 10(9):e0139043.
PMID: 26418962
PMC: 4587928.
DOI: 10.1371/journal.pone.0139043.
Human activated macrophages and hypoxia: a comprehensive review of the literature.
Sotoodehnejadnematalahi F, Burke B
Iran J Basic Med Sci. 2015; 17(11):820-30.
PMID: 25691922
PMC: 4328089.
Orchestration of angiogenesis by immune cells.
Bruno A, Pagani A, Pulze L, Albini A, Dallaglio K, Noonan D
Front Oncol. 2014; 4:131.
PMID: 25072019
PMC: 4078768.
DOI: 10.3389/fonc.2014.00131.
Click hybridization of immune cells and polyamidoamine dendrimers.
Xu L, Zolotarskaya O, Yeudall W, Yang H
Adv Healthc Mater. 2014; 3(9):1430-8.
PMID: 24574321
PMC: 4133313.
DOI: 10.1002/adhm.201300515.
Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
Foehrenbacher A, Secomb T, Wilson W, Hicks K
Front Oncol. 2014; 3:314.
PMID: 24409417
PMC: 3873531.
DOI: 10.3389/fonc.2013.00314.